PMC:7283670 / 60504-60996
Annnotations
LitCovid-PD-FMA-UBERON
{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T217","span":{"begin":179,"end":185},"obj":"Body_part"},{"id":"T218","span":{"begin":193,"end":199},"obj":"Body_part"},{"id":"T219","span":{"begin":204,"end":227},"obj":"Body_part"}],"attributes":[{"id":"A217","pred":"fma_id","subj":"T217","obj":"http://purl.org/sig/ont/fma/fma228738"},{"id":"A218","pred":"fma_id","subj":"T218","obj":"http://purl.org/sig/ont/fma/fma312401"},{"id":"A219","pred":"fma_id","subj":"T219","obj":"http://purl.org/sig/ont/fma/fma45662"}],"text":"Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases\nSecondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment)"}
LitCovid-PD-UBERON
{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T138","span":{"begin":179,"end":185},"obj":"Body_part"},{"id":"T139","span":{"begin":193,"end":199},"obj":"Body_part"},{"id":"T140","span":{"begin":204,"end":227},"obj":"Body_part"},{"id":"T141","span":{"begin":210,"end":227},"obj":"Body_part"}],"attributes":[{"id":"A138","pred":"uberon_id","subj":"T138","obj":"http://purl.obolibrary.org/obo/UBERON_0000341"},{"id":"A139","pred":"uberon_id","subj":"T139","obj":"http://purl.obolibrary.org/obo/UBERON_0007311"},{"id":"A140","pred":"uberon_id","subj":"T140","obj":"http://purl.obolibrary.org/obo/UBERON_0001558"},{"id":"A141","pred":"uberon_id","subj":"T141","obj":"http://purl.obolibrary.org/obo/UBERON_0000065"}],"text":"Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases\nSecondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment)"}
LitCovid-PD-MONDO
{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T360","span":{"begin":119,"end":127},"obj":"Disease"}],"attributes":[{"id":"A360","pred":"mondo_id","subj":"T360","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases\nSecondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment)"}
LitCovid-PD-CLO
{"project":"LitCovid-PD-CLO","denotations":[{"id":"T570","span":{"begin":204,"end":227},"obj":"http://purl.obolibrary.org/obo/UBERON_0001558"}],"text":"Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases\nSecondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment)"}
LitCovid-PD-CHEBI
{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T47677","span":{"begin":447,"end":451},"obj":"Chemical"}],"attributes":[{"id":"A41889","pred":"chebi_id","subj":"T47677","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases\nSecondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment)"}
LitCovid-PD-GO-BP
{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T44","span":{"begin":228,"end":238},"obj":"http://purl.obolibrary.org/obo/GO_0046903"}],"text":"Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases\nSecondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment)"}
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"1885","span":{"begin":307,"end":319},"obj":"Species"},{"id":"1886","span":{"begin":399,"end":411},"obj":"Species"},{"id":"2119","span":{"begin":119,"end":127},"obj":"Disease"},{"id":"2120","span":{"begin":254,"end":263},"obj":"Disease"}],"attributes":[{"id":"A1885","pred":"tao:has_database_id","subj":"1885","obj":"Tax:9606"},{"id":"A1886","pred":"tao:has_database_id","subj":"1886","obj":"Tax:9606"},{"id":"A2119","pred":"tao:has_database_id","subj":"2119","obj":"MESH:C000657245"},{"id":"A2120","pred":"tao:has_database_id","subj":"2120","obj":"MESH:D003643"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases\nSecondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment)"}